{"id":"https://openalex.org/W2109911153","doi":"https://doi.org/10.1111/j.1463-1326.2011.01545.x","title":"Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator\u2010controlled, double\u2010blind study","display_name":"Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator\u2010controlled, double\u2010blind study","alternate_titles":[],"publication_year":2012,"publication_date":"2012-01-17","ids":{"openalex":"https://openalex.org/W2109911153","doi":"https://doi.org/10.1111/j.1463-1326.2011.01545.x","mag":"2109911153","pmid":"https://pubmed.ncbi.nlm.nih.gov/22145698"},"language":"en","primary_location":{"id":"doi:10.1111/j.1463-1326.2011.01545.x","doi":"https://doi.org/10.1111/j.1463-1326.2011.01545.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2011.01545.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2109911153"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032317621","display_name":"Ryuzo Kawamori","orcid":"https://orcid.org/0000-0002-9686-9098","observed_orcids":["https://orcid.org/0000-0002-9686-9098"]},"institutions":[{"id":"https://openalex.org/I34077901","display_name":"Juntendo University","ror":"https://ror.org/01692sz90","country_code":"JP","type":"education","lineage":["https://openalex.org/I34077901"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"R. Kawamori","raw_affiliation_strings":["Sportology Centre, Juntendo University Graduate School of Medicine, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sportology Centre, Juntendo University Graduate School of Medicine, Tokyo, Japan","institution_ids":["https://openalex.org/I34077901"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077189198","display_name":"Nobuya Inagaki","orcid":"https://orcid.org/0000-0001-8261-2593","observed_orcids":["https://orcid.org/0000-0001-8261-2593"]},"institutions":[{"id":"https://openalex.org/I22299242","display_name":"Kyoto University","ror":"https://ror.org/02kpeqv85","country_code":"JP","type":"education","lineage":["https://openalex.org/I22299242"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"N. Inagaki","raw_affiliation_strings":["Kyoto University Graduate School of Medicine, Kyoto, Japan","Kyoto Univ., Graduate School of Medicine, Kyoto (Japan)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kyoto University Graduate School of Medicine, Kyoto, Japan","institution_ids":["https://openalex.org/I22299242"]},{"raw_affiliation_string":"Kyoto Univ., Graduate School of Medicine, Kyoto (Japan)","institution_ids":["https://openalex.org/I22299242"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067248419","display_name":"Eiichi Araki","orcid":"https://orcid.org/0000-0002-4064-7525","observed_orcids":["https://orcid.org/0000-0002-4064-7525"]},"institutions":[{"id":"https://openalex.org/I96036126","display_name":"Kumamoto University","ror":"https://ror.org/02cgss904","country_code":"JP","type":"education","lineage":["https://openalex.org/I96036126"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"E. Araki","raw_affiliation_strings":["Kumamoto University Graduate School of Medicine, Kumamoto, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kumamoto University Graduate School of Medicine, Kumamoto, Japan","institution_ids":["https://openalex.org/I96036126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043895658","display_name":"Hirotaka Watada","orcid":"https://orcid.org/0000-0001-5961-1816","observed_orcids":["https://orcid.org/0000-0001-5961-1816"]},"institutions":[{"id":"https://openalex.org/I34077901","display_name":"Juntendo University","ror":"https://ror.org/01692sz90","country_code":"JP","type":"education","lineage":["https://openalex.org/I34077901"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"H. Watada","raw_affiliation_strings":["Juntendo University Graduate School of Medicine, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juntendo University Graduate School of Medicine, Tokyo, Japan","institution_ids":["https://openalex.org/I34077901"]}]},{"author_position":"middle","author":{"id":null,"display_name":"N. Hayashi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122708","display_name":"Boehringer Ingelheim (Japan)","ror":"https://ror.org/02r1d7x68","country_code":"JP","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210122708"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"N. Hayashi","raw_affiliation_strings":["Boehringer Ingelheim, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim, Tokyo, Japan","institution_ids":["https://openalex.org/I4210122708"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009244618","display_name":"Yoshiharu Horie","orcid":"https://orcid.org/0000-0003-2609-2495","observed_orcids":["https://orcid.org/0000-0003-2609-2495"]},"institutions":[{"id":"https://openalex.org/I4210122708","display_name":"Boehringer Ingelheim (Japan)","ror":"https://ror.org/02r1d7x68","country_code":"JP","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210122708"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Y. Horie","raw_affiliation_strings":["Boehringer Ingelheim, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim, Tokyo, Japan","institution_ids":["https://openalex.org/I4210122708"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080582585","display_name":"Akiko Sarashina","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122708","display_name":"Boehringer Ingelheim (Japan)","ror":"https://ror.org/02r1d7x68","country_code":"JP","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210122708"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Sarashina","raw_affiliation_strings":["Boehringer Ingelheim, Hyogo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim, Hyogo, Japan","institution_ids":["https://openalex.org/I4210122708"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072564819","display_name":"Yan Gong","orcid":"https://orcid.org/0000-0002-8218-1620","observed_orcids":["https://orcid.org/0000-0002-8218-1620"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Y. Gong","raw_affiliation_strings":["Boehringer Ingelheim, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim, Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070180803","display_name":"Max von Eynatten","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. von Eynatten","raw_affiliation_strings":["Boehringer Ingelheim, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim, Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056064349","display_name":"Hans Juergen Woerle","orcid":"https://orcid.org/0000-0003-2595-1411","observed_orcids":["https://orcid.org/0000-0003-2595-1411"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"H. J. Woerle","raw_affiliation_strings":["Boehringer Ingelheim, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim, Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111521277","display_name":"Klaus A. Dugi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"K. A. Dugi","raw_affiliation_strings":["Boehringer Ingelheim, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim, Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5056064349"],"corresponding_institution_ids":["https://openalex.org/I1330995197"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":10.3686,"has_fulltext":false,"cited_by_count":118,"citation_normalized_percentile":{"value":0.98879156,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":100},"biblio":{"volume":"14","issue":"4","first_page":"348","last_page":"357"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/linagliptin","display_name":"linagliptin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/voglibose","display_name":"voglibose","score":0.9739999771118164},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9850000143051147},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.8289999961853027},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.8579999804496765},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.9610000252723694},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.8560000061988831},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6690000295639038},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.7580000162124634},{"id":"https://openalex.org/keywords/oral-antidiabetic-drugs","display_name":"oral antidiabetic drugs","score":0.5979999899864197},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5580000281333923},{"id":"https://openalex.org/keywords/drug-naive-patients","display_name":"drug-naive patients","score":0.527999997138977},{"id":"https://openalex.org/keywords/inadequate-glycemic-control","display_name":"inadequate glycemic control","score":0.597000002861023}],"concepts":[{"id":"https://openalex.org/C2780031085","wikidata":"https://www.wikidata.org/wiki/Q909745","display_name":"Linagliptin","level":4,"score":0.9949116706848145},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.854719877243042},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8424493074417114},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6633576154708862},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5542991757392883},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5463545322418213},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.532001793384552},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4620491862297058},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.45536983013153076},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4315507411956787},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.11748397350311279},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069476","descriptor_name":"Linagliptin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000704","descriptor_name":"Analysis of Variance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007294","descriptor_name":"Inositol","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D007294","descriptor_name":"Inositol","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1463-1326.2011.01545.x","doi":"https://doi.org/10.1111/j.1463-1326.2011.01545.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2011.01545.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:22145698","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22145698","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320322436","display_name":"Novo Nordisk","ror":"https://ror.org/0435rc536"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W1719308503","https://openalex.org/W1867945356","https://openalex.org/W1911149840","https://openalex.org/W1968736342","https://openalex.org/W1975588287","https://openalex.org/W2016802555","https://openalex.org/W2035979661","https://openalex.org/W2042822582","https://openalex.org/W2054599204","https://openalex.org/W2058446325","https://openalex.org/W2060124483","https://openalex.org/W2061685638","https://openalex.org/W2062945641","https://openalex.org/W2072779752","https://openalex.org/W2074142099","https://openalex.org/W2080939423","https://openalex.org/W2085770128","https://openalex.org/W2100353197","https://openalex.org/W2105028010","https://openalex.org/W2117610486","https://openalex.org/W2118186702","https://openalex.org/W2128648250","https://openalex.org/W2128766821","https://openalex.org/W2133244310","https://openalex.org/W2140480989","https://openalex.org/W2150641192","https://openalex.org/W2159416991","https://openalex.org/W2190748907"],"related_works":["https://openalex.org/W2522599189","https://openalex.org/W2035979661","https://openalex.org/W2054599204","https://openalex.org/W2042160152","https://openalex.org/W2488457804","https://openalex.org/W2104053168","https://openalex.org/W2052330038","https://openalex.org/W2043326088","https://openalex.org/W2052997601","https://openalex.org/W2066433544"],"abstract_inverted_index":{"AIMS:":[0],"To":[1],"evaluate":[2],"the":[3,89],"efficacy":[4,274],"and":[5,10,15,55,104,142,152,157,168,178,191,202,221,245,248,259,275,278,283],"safety":[6,277],"of":[7,267],"linagliptin":[8,73,98,150,176,196,199,213,218,238,242,252,256],"5":[9,74,151,177,197,214,239,253],"10":[11,76,153,179,200,219,243,257],"mg":[12,77,81,154,180,201,220,244,258],"vs.":[13,99,105,155,181],"placebo":[14,56,100,156,282],"voglibose":[16,79,106,284],"in":[17,93,193,285],"Japanese":[18,286],"patients":[19,30,59,194,287],"with":[20,31,39,72,97,212,217,223,288],"type":[21],"2":[22,51,64,66],"diabetes":[23],"mellitus":[24],"(T2DM).":[25],"METHODS:":[26],"This":[27],"study":[28],"enrolled":[29],"inadequately":[32],"controlled":[33],"T2DM":[34],"who":[35],"were":[36,46,60,113,135,161,229,263],"previously":[37],"treated":[38],"one":[40],"or":[41,45,75,83],"two":[42],"oral":[43],"antidiabetics":[44],"drug":[47],"na\u00cfve.":[48],"After":[49],"a":[50],"to":[52,69,280],"4-week":[53],"washout":[54],"run-in,":[57],"561":[58],"randomized":[61],"(2":[62],":":[63,65,67],"1)":[68],"double-blind":[70],"treatment":[71,117,130,232],"qd,":[78],"0.2":[80],"tid":[82],"placebo.":[84],"The":[85,124],"primary":[86],"endpoint":[87],"was":[88,122,188,210],"change":[90],"from":[91],"baseline":[92],"haemoglobin":[94],"A1c":[95],"(HbA1c)":[96],"after":[101,107],"12":[102,134,235],"weeks":[103,236,250],"26":[108,160,249],"weeks.":[109],"RESULTS:":[110],"Baseline":[111],"characteristics":[112],"well":[114],"balanced":[115],"across":[116,231],"groups":[118,233],"(overall":[119],"mean":[120,126,186,208],"HbA1c":[121,187,209],"8.01%).":[123],"adjusted":[125],"(95%":[127],"confidence":[128],"interval)":[129],"differences":[131],"at":[132,158],"week":[133,159,184,206],"-0.87%":[136],"(-1.04,":[137],"-0.70;":[138],"p":[139,146,165,172],"<":[140,147,173],"0.0001)":[141,148,174],"-0.88%":[143],"(-1.05,":[144],"-0.71;":[145],"for":[149,175],"-0.32%":[162],"(-0.49,":[163],"-0.15;":[164],"=":[166],"0.0003)":[167],"-0.39%":[169],"(-0.56,":[170],"-0.21;":[171],"voglibose.":[182,224],"At":[183,205],"12,":[185],"7.58,":[189],"7.48":[190],"8.34%":[192],"receiving":[195],"mg,":[198,215,240,254],"placebo,":[203],"respectively.":[204],"26,":[207],"7.63%":[211],"7.50%":[216],"7.91%":[222],"Drug-related":[225],"adverse":[226],"event":[227],"rates":[228],"comparable":[230,276],"over":[234],"(9.4%":[237],"8.8%":[241],"10.0%":[246],"placebo)":[247],"(11.3%":[251],"10.6%":[255],"18.5%":[260],"voglibose).":[261],"There":[262],"no":[264],"documented":[265],"cases":[266],"hypoglycaemia.":[268],"CONCLUSIONS:":[269],"Linagliptin":[270],"showed":[271],"superior":[272],"glucose-lowering":[273],"tolerability":[279],"both":[281],"T2DM.":[289]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2109911153","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":12},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":13},{"year":2014,"cited_by_count":17},{"year":2013,"cited_by_count":16},{"year":2012,"cited_by_count":9}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
